Dermatologic and Allergic Conditions of the Eyelid

Immunology and Allergy Clinics of North America

Volumn 28, Issue 1, 2008, Pages 137-168

  Peralejo, Belle ^a   Beltrani, Vincent ^a,b   Bielory, Leonard ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Columbia University ^*  (United States)

^c INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BLEOMYCIN; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; DIPIVEFRINE; ERYTHROMYCIN; FLUOROURACIL; IDOXURIDINE; INSULIN; MERCURY; NEOMYCIN; NICKEL; PENICILLIN DERIVATIVE; PIMECROLIMUS; PODOPHYLLIN; POLYSPORIN; PSEUDOMONIC ACID; RETINOIC ACID; SALICYLIC ACID; STEROID; TACROLIMUS; TETRACYCLINE; TRICHLOROACETIC ACID; TRIFLURIDINE; UNINDEXED DRUG; VALACICLOVIR; VIDARABINE;

ACNE; ALLERGIC URTICARIA; ANGIONEUROTIC EDEMA; ATOPIC DERMATITIS; BASAL CELL CARCINOMA; BLEPHARITIS; BURN; CATARACT; CHALAZION; CLINICAL TRIAL; COMEDO; CONJUNCTIVITIS; CONTACT DERMATITIS; CONTACT URTICARIA; ERYSIPELAS; EYE ALLERGY; EYE INFECTION; EYE INFLAMMATION; EYE TUMOR; FIBROMA; GLAUCOMA; HEMANGIOMA; HERPES SIMPLEX; HERPES ZOSTER; HORDEOLUM; HUMAN; HYPERSENSITIVITY; INFECTION RISK; LIPOID PROTEINOSIS; MELANOMA; META ANALYSIS; NEVUS; NEVUS FLAMMEUS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PYODERMA; RASH; REVIEW; ROSACEA; SARCOIDOSIS; SEBACEOUS CARCINOMA; SEBORRHEIC DERMATITIS; SEBORRHEIC KERATOSIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SYRINGOMA; SYSTEMATIC REVIEW; TELANGIECTASIA; TRICHINOSIS; UNSPECIFIED SIDE EFFECT; VASCULAR LESION; VERRUCA VULGARIS; VITILIGO; XANTHOMA;

BLEPHARITIS; DERMATITIS, SEBORRHEIC; EYELIDS; HUMANS; HYPERSENSITIVITY; SKIN DISEASES; VITILIGO;

EID: 39049157746     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2007.12.004     Document Type: Review

References (152)

1. Kanitakis J. Anatomy, histology and immunohistochemistry of normal human skin. Eur J Dermatol 12 4 (2002) 390-399 [quiz: 400-1]
2. Ha R.Y., Nojima K., Adams Jr. W.P., et al. Analysis of facial skin thickness: defining the relative thickness index. Plast Reconstr Surg 115 6 (2005) 1769-1773
3. Fitzpatrick T.B., and Freedberg I.M. Fitzpatrick's dermatology in general medicine. 6th edition (2003), McGraw-Hill, New York Medical Pub. Division. xxxi, p. 2594
4. Gupta A.K., Madzia S.E., and Batra R. Etiology and management of seborrheic dermatitis. Dermatology 208 2 (2004) 89-93
5. Gupta A.K., Batra R., Bluhm R., et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol 51 5 (2004) 785-798
6. Gupta A.K., Bluhm A.R., Cooper E.A., et al. Seborrheic dermatitis. Dermatol Clin 21 3 (2003) 401-412
7. Rigopoulos D., Paparizos V., Katsambas A., et al. Cutaneous markers of HIV infection. Clin Dermatol 22 6 (2004) 487-498
8. Rallis E., Nasiopoulou A., Kouskoukis C., et al. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res 30 5-6 (2004) 191-195
9. Sehgal V.N., and Srivastava G. Vitiligo: auto-immunity and immune responses. Int J Dermatol 45 5 (2006) 583-590
10. Ongenae K., Van Geel N., and Naeyaert J.M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 16 2 (2003) 90-100
11. Barnes L. Vitiligo and the Vogt-Koyanagi-Harada syndrome. Dermatol Clin 6 2 (1988) 229-239
12. Amerio P., Tracanna M., De Remigis P., et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol 31 5 (2006) 746-749
13. Gould I.M., Gray R.S., Urbaniak S.J., et al. Vitiligo in diabetes mellitus. Br J Dermatol 113 2 (1985) 153-155
14. Handa S., and Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol 26 10 (1999) 653-657
15. Hwang S.M., Ahn S.K., and Choi E.H. Psoriasis occurring in amelanotic lesions. J Dermatol 25 1 (1998) 66-67
16. Rubisz-Brzezinska J., Buchner S.A., and Itin P. Vitiligo associated with lichen planus. Is there a pathogenetic relationship?. [see comment]. Dermatology 192 2 (1996) 176-178
17. Lever W.F., and Elder D.E. Lever's histopathology of the skin. 9th edition (2005), Lippincott Williams & Wilkins, Philadelphia xvi, p. 1229
18. Janis J.F., and Winkelmann R.K. Histopathology of the skin in dermatomyositis. A histopathologic study of 55 cases. Arch Dermatol 97 6 (1968) 640-650
19. Habif T.P. Clinical dermatology: a color guide to diagnosis and therapy. 3rd edition (1996), Mosby, St. Louis xii, p. 898
20. Bergma R. The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 30 2 Pt 1 (1994) 236-242
21. Rohrich R.J., Janis J.E., and Pownell P.H. Xanthelasma palpebrarum: a review and current management principles. Plast Reconstr Surg 110 5 (2002) 1310-1314
22. Scriver C.R. The metabolic basis of inherited disease. 6th edition (1989), McGraw-Hill Information Services Co.,, New York Health Professions Division. 2 v. (xxviii, 3006, 85 p.)
23. Stawiski M.A., and Voorhees J.J. Cutaneous signs of diabetes mellitus. Cutis 18 3 (1976) 415-421
24. Varma J.R. Skin tags:-a marker for colon polyps?. J Am Board Fam Pract 3 3 (1990) 175-180
25. Piette A.M., Meduri B., Fritsch J., et al. Do skin tags constitute a marker for colonic polyps? A prospective study of 100 asymptomatic patients and metaanalysis of the literature. Gastroenterology 95 4 (1988) 1127-1129
26. Cox J.T. Epidemiology and natural history of HPV. J Fam Pract Suppl (2006) 3-9
27. Jackson R. Elderly and sun-affected skin. Distinguishing between changes caused by aging and changes caused by habitual exposure to sun. Can Fam Physician 47 (2001) 1236-1243
28. Schepis C., Siragusa M., Palazzo R., et al. Palpebral syringomas and Down's syndrome. Dermatology 189 3 (1994) 248-250
29. Buechner S.A. Rosacea: an update. Dermatology 210 2 (2005) 100-108
30. Roihu T., and Kariniemi A.L. Demodex mites in acne rosacea. J Cutan Pathol 25 10 (1998) 550-552
31. Mannis MJ, Macsai MS, Huntley AC. Eye and skin disease. Philadelphia: 1996. Lippincott-Raven; xxiii, 705 p.
32. Starr P.A. Oculocutaneous aspects of rosacea. Proc R Soc Med 62 1 (1969) 9-11
33. Stone D.U., and Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol 15 6 (2004) 499-502
34. Ghanem V.C., Mehra N., Wong S., et al. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 22 3 (2003) 230-233
35. Bozda K.E., Gul Y., and Karaman A. Lipoid proteinosis. Int J Dermatol 39 3 (2000) 203-204
36. Thappa D.M., Gupta S., Thappa D.M., et al. Eyelid beading-a useful diagnostic clue for lipoid proteinosis. Indian Pediatr 38 1 (2001) 97
37. Sicherer S.H., Sampson H.A., Sicherer S.H., et al. 9. Food allergy. J Allergy Clin Immunol 117 2 Suppl Mini-Primer (2006) S470-S475
38. Wuthrich B., and Wuthrich B. Food-induced cutaneous adverse reactions. Allergy 53 46 (1998) 131-135
39. Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters of the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 83 6 Pt 3 (1999) 665-700
40. Golden D.B., and Golden D.B.K. Stinging insect allergy. Am Fam Physician 67 12 (2003) 2541-2546
41. Byrd J.B., Adam A., Brown N.J., et al. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 26 4 (2006) 725-737
42. Ben Simon G.J., Huang L., Nakra T., et al. Intralesional triamcinolone acetonide injection for primary and recurrent chalazia: is it really effective?. [see comment]. Ophthalmology 112 5 (2005) 913-917
43. Greve B., and Raulin C. [Medical dermatologic laser therapy. A review]. Hautarzt 54 7 (2003) 594-602 [in German]
44. van de Kerkhof P.C., de Rooij M., and Steijlen P.M. Spontaneous course of hemangiomas: facts and speculations. Int J Dermatol 37 2 (1998) 101-102
45. Lindgren G., Diffey B.L., and Larko O. Basal cell carcinoma of the eyelids and solar ultraviolet radiation exposure. Br J Ophthalmol 82 12 (1998) 1412-1415
46. Cook Jr. B.E., and Bartley G.B. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology 106 4 (1999) 746-750
47. Rishi K., and Font R.L. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review. [see comment] [erratum appears in Ophthal Plast Reconstr Surg. 2004 May;11(5):953]. Ophthal Plast Reconstr Surg 20 1 (2004) 31-36
48. Garner A., Koornneef L., Levene A., et al. Malignant melanoma of the eyelid skin: histopathology and behaviour. Br J Ophthalmol 69 3 (1985) 180-186
49. Chan F.M., O'Donnell B.A., Whitehead K., et al. Treatment and outcomes of malignant melanoma of the eyelid: a review of 29 cases in Australia. Ophthalmology 114 1 (2007) 187-192
50. Zug K.A., Palay D.A., and Rock B. Dermatologic diagnosis and treatment of itchy red eyelids. Surv Ophthalmol 40 4 (1996) 293-306
51. Svensson A., and Moller H. Eyelid dermatitis: the role of atopy and contact allergy. Contact Dermatitis 15 3 (1986) 178-182
52. Nethercott J.R., Nield G., and Holness D.L. A review of 79 cases of eyelid dermatitis. J Am Acad Dermatol 21 2 Pt 1 (1989) 223-230
53. Valsecchi R., Imberti G., Martino D., et al. Eyelid dermatitis: an evaluation of 150 patients. Contact Dermatitis 27 3 (1992) 143-147
54. Amin K.A., and Belsito D.V. The aetiology of eyelid dermatitis: a 10-year retrospective analysis. Contact Dermatitis 55 5 (2006) 280-285
55. Browning D.J., and Proia A.D. Ocular rosacea. Surv Ophthalmol 31 3 (1986) 145-158
56. Guin J.D. Eyelid dermatitis: a report of 215 patients. Contact Dermatitis 50 2 (2004) 87-90
57. Ayala F., Fabbrocini G., Bacchilega R., et al. Eyelid dermatitis: an evaluation of 447 patients. Am J Contact Dermat 14 2 (2003) 69-74
58. Hanifin J.M., and Lobitz Jr. W.C. Newer concepts of atopic dermatitis. Arch Dermatol 113 5 (1977) 663-670
59. Leung D.Y. Role of IgE in atopic dermatitis. Curr Opin Immunol 5 6 (1993) 956-962
60. Wahlgren C.F., Hagermark O., and Bergstrom R. Patients' perception of itch induced by histamine, compound 48/80 and wool fibres in atopic dermatitis. Acta Derm Venereol 71 6 (1991) 488-494
61. O'Donnell B.F., and Foulds I.S. Contact allergic dermatitis and contact urticaria due to topical ophthalmic preparations. Br J Ophthalmol 77 11 (1993) 740-741
62. Baker B.S. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 144 1 (2006) 1-9
63. Guin J.D. Eyelid dermatitis: experience in 203 cases. J Am Acad Dermatol 47 5 (2002) 755-765
64. Draelos Z.D. Special considerations in eye cosmetics. Clin Dermatol 19 4 (2001) 424-430
65. de Groot A.C. Contact allergy to cosmetics: causative ingredients. Contact Dermatitis 17 1 (1987) 26-34
66. Bielory L. Contact dermatitis of the eyelids. Immunol Allergy Clin North Am 17 1 (1997) 131-138
67. Goossens A. Contact allergic reactions on the eyes and eyelids. Bull Soc Belge Ophtalmol 292 (2004) 11-17
68. Rietschel R.L., Warshaw E.M., Sasseville D., et al. Common contact allergens associated with eyelid dermatitis: data from the North American Contact Dermatitis Group 2003-2004 study period. Dermatitis 18 2 (2007) 78-81
69. Krob H.A., Fleischer Jr. A.G., D'Agostino R., et al. Prevalence and relevance of contact dermatitis allergens: a meta-analysis of 15 years of published T.R.U.E. test data. J Am Acad Dermatol 51 3 (2004) 349-353
70. Beltrani V.S. Eyelid dermatitis. Curr Allergy Asthma Rep 1 4 (2001) 380-388
71. Groot A., Weyland J.W., and Nater J.P. Unwanted effects of cosmetics and drugs used in dermatology. 3rd edition (1994), Elsevier, Amsterdam; New York xii, 770 p
72. Hansson C., Weyland J.W., Nater N.P., et al. Allergic contact dermatitis from 2-chloro-p-phenylenediamine in a cream dye for eyelashes and eyebrows. Contact Dermatitis 45 4 (2001) 235-236
73. Teixeira M., de Wachter L., Ronsyn E., et al. Contact allergy to para-phenylenediamine in a permanent eyelash dye. Contact Dermatitis 55 2 (2006) 92-94
74. Wachsmuth R., and Wilkinson M. Loss of eyelashes after use of a tinting mascara containing PPD. Contact Dermatitis 54 3 (2006) 169-170
75. Fisher A.A. Allergic contact dermatitis from Germall 115, a new cosmetic preservative. Contact Dermatitis 1 2 (1975) 126
76. Fisher A.A., and Fisher A.A. Cutaneous reactions to sorbic acid and potassium sorbate. Cutis 25 4 (1980) 350
77. Thompson D.A., and Tan B.B. Tetrahydracurcumin-related allergic contact dermatitis. Contact Dermatitis 55 4 (2006) 254-255
78. Le Coz C.J., Leclere J.M., Arnoult E., et al. Allergic contact dermatitis from shellac in mascara. Contact Dermatitis 46 3 (2002) 149-152
79. Fisher A.A., and Fisher A.A. Allergic contact dermatitis due to rosin (colophony) in eyeshadow and mascara. Cutis 42 6 (1988) 507-508
80. Rapaport M.J., and Rapaport M.J. Sensitization to Abitol. Contact Dermatitis 6 2 (1980) 137
81. Dooms-Goossens A., Degreef G., Luytens E., et al. Dihydroabietyl alcohol (Abitol): a sensitizer in mascara. Contact Dermatitis 5 6 (1979) 350-353
82. Calnan C.D., and Calnan C.D. Quinazoline yellow SS in cosmetics. Contact Dermatitis 2 3 (1976) 160-166
83. Pratt M.D., Belsito D.V., DeLeo V.A., et al. North American Contact Dermatitis Group patch-test results, 2001-2002 study period. Dermatitis 15 4 (2004) 176-183
84. Panati C. Extraordinary origins of everyday things. 1st edition (1987), Harper & Row, New York xi, 463
85. Nassif A.S., Le Coz C.J., and Collet E. A rare nail polish allergen: phthalic anhydride, trimellitic anhydride and glycols copolymer. Contact Dermatitis 56 3 (2007) 172-173
86. Guin J.D., and Guin J.D. Eyelid dermatitis from methacrylates used for nail enhancement. Contact Dermatitis 39 6 (1998) 312-313
87. Garner L.A., and Garner L.A. Contact dermatitis to metals. Dermatol Ther 17 4 (2004) 321-327
88. Herbst R.A., Maibach H.I., Herbst R.A., et al. Allergic contact dermatitis from ophthalmics: update 1997. Contact Dermatitis 37 5 (1997) 252-253
89. Burge S.M., Powell S.M., Burge S.M., et al. Contact urticaria to phosphorus sesquisulphide. Contact Dermatitis 9 5 (1983) 424
90. Prystowsky S.D., Allen A.M., Smith R.W., et al. Allergic contact hypersensitivity to nickel, neomycin, ethylenediamine, and benzocaine. Relationships between age, sex, history of exposure, and reactivity to standard patch tests and use tests in a general population. Arch Dermatol 115 8 (1979) 959-962
91. van Ketel W.G., Melzer-van Riemsdijk F.A., van Ketel W.G., et al. Conjunctivitis due to soft lens solutions. Contact Dermatitis 6 5 (1980) 321-324
92. Seitz C.S., Brocker E.B., Trautmannn A., et al. Eyelid dermatitis due to sodium metabisulfite. Contact Dermatitis 55 4 (2006) 249-250
93. Lai C.H., Lai I.C., Chi C.C., et al. Allergic contact dermatitis caused by latanoprost ophthalmic solution. Eur J Ophthalmol 16 4 (2006) 627-629
94. Gaspari A.A., and Gaspari A.A. Contact allergy to ophthalmic dipivalyl epinephrine hydrochloride: demonstration by patch testing. Contact Dermatitis 28 1 (1993) 35-37
95. Schempp C.M., Schopf E., Simon J.C., et al. [Plant-induced toxic and allergic dermatitis (phytodermatitis)]. Hautarzt 53 2 (2002) 93-97 [in German]
96. Gladman A.C., and Gladman A.C. Toxicodendron dermatitis: poison ivy, oak, and sumac. Wilderness Environ Med 17 2 (2006) 120-128
97. Belsito D.V., and Belsito D.V. Patch testing with a standard allergen ("screening") tray: rewards and risks. Dermatol Ther 17 3 (2004) 231-239
98. de Groot A.C., Frosch P.J., de Groot A.C., et al. Adverse reactions to fragrances. A clinical review. Contact Dermatitis 36 2 (1997) 57-86
99. Barker M.O. Newer cosmetic ingredients:-new patch testing problems?. Am J Contact Dermat 9 2 (1998) 130-135
100. Cosmetic Toiletry and Fragrance Association. Cosmetic industry on call (1982), Cosmetic, Toiletry, and Fragrance Association, Washington, DC p. 38
101. de Groot A.C., van Ginkel C.J., Weijland J.W., et al. [Statement of ingredients of cosmetics]. Ned Tijdschr Geneeskd 141 36 (1997) 1747-1748 [in Dutch]
102. Pepose J.S., Holland G.N., and Wilhelmus K.R. Ocular infection & immunity (1996), Mosby, St. Louis xl. 1552 p
103. Zaal M.J., Volker-Dieben H.J., and D'Amaro J. Prognostic value of Hutchinson's sign in acute herpes zoster ophthalmicus. Graefes Arch Clin Exp Ophthalmol 241 3 (2003) 187-191
104. Turpeinen M., Salo O.P., Leisti S., et al. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 115 4 (1986) 475-484
105. Hoare C., Li Wan Po A., Williams H., et al. Systematic review of treatments for atopic eczema. Health Technol Assess 4 37 (2000) 1-191
106. Del Rosso J., Friedlander S.F., Del Rosso J., et al. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol 53 1 Suppl 1 (2005) S50-S58
107. Staab D., Pariser D., Gottlieb A.B., et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis: a multicenter, 3-week, open-label study. Pediatr Dermatol 22 5 (2005) 465-471
108. Harper J., Smith C., Rubins A., et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 124 4 (2005) 695-699
109. Reitamo S., Rustin M., Ruzicka T., et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 109 3 (2002) 547-555
110. Housman T.S., Norton A.B., Feldman S.R., et al. Tacrolimus ointment: utilization patterns in children under age 2 years. Dermatol Online J 10 1 (2004) 2
111. Boguniewicz M., Fiedler V.C., Raimer S., et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. [see comment]. J Allergy Clin Immunol 102 4 Pt 1 (1998) 637-644
112. Fonacier L., Spergel J., Charlesworth E.N., et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 115 6 (2005) 1249-1253
113. Kaufman H.E. Treatment of viral diseases of the cornea and external eye. Prog Retin Eye Res 19 1 (2000) 69-85
114. Liesegang T.J., and Liesegang T.J. Herpes zoster virus infection. Curr Opin Ophthalmol 15 6 (2004) 531-536
115. Gibbs S., Harvey I., Gibbs S., et al. Topical treatments for cutaneous warts. [update of Cochrane Database Syst Rev 2003;(3):CD001781; PMID: 12917913]. Cochrane Database Syst Rev 3 (2006) CD001781
116. Snoeck R. Papillomavirus and treatment. Antiviral Res 71 2-3 (2006) 181-191
117. Hanson D., and Diven D.G. Molluscum contagiosum. Dermatol Online J 9 2 (2003) 2
118. Smith K.J., and Skelton H. Molluscum contagiosum: recent advances in pathogenic mechanisms, and new therapies. Am J Clin Dermatol 3 8 (2002) 535-545
119. van Zuuren E.J., Gupta A.K., Gover M.D., et al. Systematic review of rosacea treatments. J Am Acad Dermatol 56 1 (2007) 107-115
120. van Zuuren E.J., Graber M.A., Hollis S., et al. Interventions for rosacea. [update of Cochrane Database Syst Rev 2004;(1):CD003262; PMID: 14974010]. Cochrane Database Syst Rev 3 (2005) CD003262
121. Stone D.U., and Chodosh J. Oral tetracyclines for ocular rosacea: an evidence-based review of the literature. Cornea 23 1 (2004) 106-109
122. Berman B., Perez O.A., and Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today 43 1 (2007) 27-34
123. Fowler Jr. J.F. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 6 6 (2007) 641-645
124. Yoo J., Reid D.C., and Kimball A.B. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter?. J Drugs Dermatol 5 4 (2006) 317-319
125. Levy J.H., O'Donnell P.S., Levy J.H., et al. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 15 9 (2006) 1077-1090
126. Bas M., Adams V., Suvorava T., et al. Nonallergic angioedema: role of bradykinin. Allergy 62 8 (2007) 842-856
127. Bork K., Frank J., Grundt B., et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 119 6 (2007) 1497-1503
128. Lock R.J., and Gompels M.M. C1-inhibitor deficiencies (hereditary angioedema): where are we with therapies?. Curr Allergy Asthma Rep 7 4 (2007) 264-269
129. Zuraw B.L. Current and future therapy for hereditary angioedema. Clin Immunol 114 1 (2005) 10-16
130. Park H.J., Lee D.Y., Lee J.H., et al. The treatment of syringomas by CO(2) laser using a multiple-drilling method. Dermatol Surg 33 3 (2007) 310-313
131. Wang J.I., and Roenigk Jr. H.H. Treatment of multiple facial syringomas with the carbon dioxide (CO2) laser. Dermatol Surg 25 2 (1999) 136-139
132. Ruban J.M. [Treatment of benign eyelid conditions with argon laser]. J Fr Ophtalmol 26 1 (2003) 88-91 [in French]
133. Raulin C., Schonermark M.P., Greve B., et al. Q-switched ruby laser treatment of tattoos and benign pigmented skin lesions: a critical review. Ann Plast Surg 41 5 (1998) 555-565
134. Ferguson Jr. R.E.H., and Vasconez H.C. Laser treatment of congenital nevi. J Craniofac Surg 16 5 (2005) 908-914
135. Chan H.H.L., and Kono T. Nevus of Ota: clinical aspects and management. Skinmed 2 2 (2003) 89-96 [quiz: 97-8]
136. Ee H.L., Goh C.L., Khoo L.S., et al. Treatment of acquired bilateral nevus of Ota-like macules (Hori's nevus) with a combination of the 532 nm Q-switched Nd:YAG laser followed by the 1,064 nm Q-switched Nd:YAG is more effective: prospective study. Dermatol Surg 32 1 (2006) 34-40
137. Pieh S., Kuchar A., Novak P., et al. Long-term results after surgical basal cell carcinoma excision in the eyelid region. Br J Ophthalmol 83 1 (1999) 85-88
138. Limawararut V., Leibovitch I., Sullivan T., et al. Periocular squamous cell carcinoma. [see comment]. Clin Experiment Ophthalmol 35 2 (2007) 174-185
139. Spencer J.M., Nossa R., Tse D.T., et al. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol 44 6 (2001) 1004-1009
140. Zurcher M., Hintschich C.R., Garner A., et al. Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol 82 9 (1998) 1049-1055
141. O'Keefe M., Lanigan B., and Byrne S.A. Capillary haemangioma of the eyelids and orbit: a clinical review of the safety and efficacy of intralesional steroid. Acta Ophthalmologica Scandinavica 81 3 (2003) 294-298
142. Garzon M.C., Lucky A.W., Hawrot A., et al. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 52 2 (2005) 281-286
143. Railan D., Parlette E.C., Uebelhoer N.S., et al. Laser treatment of vascular lesions. Clin Dermatol 24 1 (2006) 8-15
144. Yones S.S., Palmer R.A., Garibaldinos T.M., et al. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. [see comment]. Arch Dermatol 143 5 (2007) 578-584
145. Bhatnagar A., Kanwar A.J., Parsad D., et al. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol 21 5 (2007) 638-642
146. Forschner T., Buchholtz S., and Stockfleth E. Current state of vitiligo therapy: evidence-based analysis of the literature. J Dtsch Dermatol Ges 5 6 (2007) 467-475
147. Choy E.H.S., and Isenberg D.A. Treatment of dermatomyositis and polymyositis. Rheumatology 41 1 (2002) 7-13
148. Wallace D.J. The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 5 Suppl 1 (1996) S59-S64
149. Cohen J.B. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. Int J Dermatol 41 3 (2002) 182-184
150. Brasington Jr. R.D., Kahl Jr. L.E., Ranganathan P., et al. 14. Immunologic rheumatic disorders. J Allergy Clin Immunol 111 Suppl 2 (2003) S593-S601
151. Reiff A., Rawlings D.J., Shaham B., et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 24 12 (1997) 2436-2443
152. Gelber A.C., Nousari H.C., and Wigley F.M. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 27 6 (2000) 1542-1545